INS and diabetes mellitus: Most patients with KCNJ11 and ABCC8 mutations have isolated diabetes, and their treatment can be switched from subcutaneous insulin injections to treatment with oral sulfonylureas (SU) (Bowman et al., 2018; Pearson et al., 2006).